- /
- Supported exchanges
- / US
- / IBRX.NASDAQ
Immunitybio Inc (IBRX NASDAQ) stock market data APIs
Immunitybio Inc Financial Data Overview
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunitybio Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Immunitybio Inc data using free add-ons & libraries
Get Immunitybio Inc Fundamental Data
Immunitybio Inc Fundamental data includes:
- Net Revenue: 82 555 K
- EBITDA: -244 947 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.1071
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunitybio Inc News
New
ImmunityBio (IBRX): Assessing Valuation After Q3 Revenue Surge and Narrowed Losses
ImmunityBio (IBRX) posted third quarter earnings, highlighting a sharp jump in revenue and a narrower net loss compared to last year. Investors are watching closely because these results mark a shift ...
How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook
Earlier this month, ImmunityBio, Inc. reported third quarter and nine-month earnings, with revenue rising to US$32.06 million and US$75 million, alongside narrowing net losses compared to the prior ye...
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Insights show patients with non-muscle invasive bladder cancer want to explore new treatment options, yet fewer than one in five say their doctors discuss all available procedures/treatments at most o...
ImmunityBio: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Tuesday reported a loss of $67.3 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss o...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.